MedTrace Logo

Ketogenic Diet for Recurrent Glioblastoma

NCT00575146 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-05-02

Study results available
· View outcomes & findings →

Summary

To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma

Conditions

Interventions

DIETARY_SUPPLEMENT

TAVARLIN

ketogenic diet, dietary supplementary products provided by TAVARLIN

Sponsors & Collaborators

  • Evomed MedizinService GmbH

    collaborator UNKNOWN

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Johannes Rieger, MD · Senckenberg Institute of Neurooncology, University of Frankfurt

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00575146 on ClinicalTrials.gov